IP Library Granted Patent US 9,050,190
Granted Patent B2
US 9,050,190 · App. 12/922,534 · Granted Jun 9, 2015

Device comprising a swelling agent and sheathing for artificial callus distraction

Inventor: Domonkos Horvath (Jestetten, DE)
Assignee: CELGEN3D AG
A61F2/28A61B17/666A61B2017/00898A61L27/34A61L27/50A61L2430/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,050,190
App. No.
12/922,534
Granted
Jun 9, 2015
Kind
B2
Abstract

A device for regenerating a bone includes a sheathing and a swelling agent. At least a portion of the sheathing has the shape of a bellows, and/or the exterior of the sheathing bears at least one lamella. The swelling agent is enclosed by the sheathing. The sheathing is biocompatible, expandable, contractible, and/or deformable in a predefined and controlled manner as a function of a force effect induced by a change in volume of the swelling agent.

Claims (52)

1. A granulate for regenerating a bone, the granulate comprising:

a first device; and

a second device;

the first and second devices both including:

a sheathing, at least a portion of the sheathing having a predefined shape in the form of a bellows; and

a swelling agent completely enclosed by the sheathing for changing the shape of the sheathing in a predefined and controlled manner as a function of a force effect induced by a change in volume of the swelling agent the swelling agent cooperating with the sheathing such that a starting volume of the swelling agent changes at a predetermined rate and that a maximum rate at which the starting volume of the swelling agent is able to change is sufficient to distract cells adhering to the device a maximum of 1.5 mm per day;

wherein the first and second devices cooperate to define the granulate.

2. The granulate according to claim 1 , wherein a change in volume of the swelling agent is induced by the swelling agent as a result of absorption of liquid.

3. The granulate according to claim 1 , wherein the swelling agent is a hydrogel.

4. The granulate according to claim 1 , wherein the each sheathing contains a material selected from a group consisting of: polyglycolic acid, polylactic acid, poly(ε-caprolactone), poly(β-hydroxybutyrate), poly(p-dioxanone), a polyanhydride, and mixtures thereof.

5. The granulate according to claim 1 , wherein both of the sheathings are composed of polylactic acid.

6. The granulate according to claim 1 , wherein the sheathings of both the first and second devices are composed of poly(ε-caprolactone).

7. The granulate according to claim 1 , wherein the sheathings of both the first and second devices are biodegradable.

8. The device according to claim 1 , wherein the sheathings of both the first and second devices are porous.

9. The device according to claim 1 , wherein at least a portion of each sheathing has the shape of a tube.

10. The granulate according to claim 1 , wherein the exterior of each sheathing bears at least one framework.

11. The granulate according to claim 1 , wherein the first and second devices are connected to one another via at least one lamella.

12. The granulate according to claim 1 , wherein the first and second devices are connected to one another via at least one framework.

13. The granulate according to claim 1 , wherein the change in volume of the swelling agent is induced by the swelling agent as a result of absorption of liquid containing biomolecules or cells.

14. The granulate according to claim 1 , wherein the change in volume of the swelling agent is induced by the swelling agent as a result of absorption of blood.

15. The granulate according to claim 1 , wherein an exterior of the sheathings of the first and second devices are connected by at least two lamella, each sheathing having the shape of a bellows.

16. The granulate for regenerating a bone of claim 1 , wherein the first and second devices are fixed to one another with a biodegradable adhesive.

17. The granulate for regenerating a bone of claim 1 , wherein the granulate is injectable into a bone defect with a syringe.

18. A method for regenerating a bone, the method comprising:

providing a granulate including:

a first device; and

a second device;

the first and second devices both including:

a sheathing, at least a portion of the sheathing having a predefined shape in the form of a bellows; and

a swelling agent completely enclosed by the sheathing for changing the shape of the sheathing in a predefined and controlled manner as a function of a force effect induced by a change in volume of the swelling agent the swelling agent cooperating with the sheathing such that a starting volume of the swelling agent changes at a predetermined rate and that a maximum rate at which the starting volume of the swelling agent is able to change is sufficient to distract cells adhering to the device a maximum of 1.5 mm per day;

wherein the first and second devices cooperate to define the granulate;

introducing the granulate into a defect region of a bone; and

exposing the sheathing to a force effect as the result of the change in volume of the swelling agent.

19. The method according to claim 18 , wherein the step of introducing the granulate into a defect region of a bone includes contacting the swelling agent with a liquid.

20. The method according to claim 18 , further comprising revivifying the defect region of the bone before the granulate is introduced.

21. A granulate for regenerating a bone comprising:

first and second devices each including a sheathing;

a swelling agent enclosed by each of the sheathings, the swelling agent cooperating with a sheathing for changing a shape of the sheathing in a predefined and controlled manner as a function of a force effect induced by a change in volume of the swelling agent; and

at least two rigid lamellae extending distally between the sheathings of the first and second devices to generate a gridded framework;

wherein the sheathing and the swelling agent of both the first and second devices cooperate such that a starting volume of the swelling agent changes at a predetermined rate and that a maximum rate at which the starting volume of the swelling agent is able to change is sufficient to distract cells adhering to the device a maximum of 1.5 mm per day.

22. The granulate of claim 21 , wherein the at least two lamellae includes at least one rod-shaped lamella.

23. The granulate of claim 21 , wherein at least a portion of the sheathings of both the first and second devices has a predefined shape in the form of a bellows having a plurality of folds and wherein each rod-shaped lamella extends from a fold of the sheathing.

24. The granulate of claim 21 , wherein the sheathing of both the first and second devices includes a first end and a second end and is elongated along an axis, and further wherein the at least two lamellae includes at least a pair of lamella spaced apart from both the first and second ends along a length of the sheathing.

25. The granulate for regenerating a bone of claim 21 , wherein the granulate is injectable into a bone defect with a syringe.

26. A granulate for regenerating a bone, the granulate comprising:

a first device; and

a second device;

the first and second devices both including:

a porous sheathing comprising pores having a maximum size of 2 μm, at least a portion of the sheathing having a predefined shape in the form of a bellows;

a swelling agent completely enclosed by the sheathing for changing the shape of the sheathing in a predefined and controlled manner as a function of a force effect induced by a change in volume of the swelling agent the swelling agent cooperating with the sheathing such that a starting volume of the swelling agent changes at a predetermined rate and that a maximum rate at which the starting volume of the swelling agent is able to change is sufficient to distract cells adhering to the device a maximum of 1.5 mm per day; and

at least two rigid lamellae extending distally between the sheathings of the first and second devices to generate a gridded framework to define the granulate,

wherein the first and second devices are configured to allow liquid to penetrate the sheathing through the pores and contact the swelling agent to cause the swelling agent to expand.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2014
From: CELGEN AG
To: CELGEN3D AG
Reel/Frame 032815/0667 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2010
From: HORVATH, DOMONKOS
To: CELGEN AG
Reel/Frame 024985/0875 →
Priority Claims (1)
DE 10 2008 014 560 · Mar 15, 2008 · national
Continuity (1)
Related Publication 20110009978A1 · Jan 13, 2011